ArticleBMC infectious diseases2026
Association of Shenfu injection with reduced 28-day mortality in critically ill patients with sepsis: a retrospective propensity score-matched cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveWe aimed to investigate the association between the combination of shenfu injection (SFI) and sepsis bundle therapy and clinical outcomes in critically ill patients with sepsis in China.
methodsThis retrospective cohort study was conducted using Electronic Health Records (EHR) from Ruijin Hospital, affiliated with Shanghai Jiaotong University School of Medicine. Adult critically ill patients diagnosed with sepsis between January 2013 and December 2023 were included in the analysis. The decision to administer SFI was made by the attending physician. The primary outcome was 28-day mortality. Secondary outcomes included ICU length of stay (LOS), hospital LOS, ventilation-free days, vasopressor-free days, procalcitonin clearance rate, lactate clearance rate, and D-dimer serum levels. Propensity score matching was used to minimize bias when comparing patients who received SFI treatment to those who did not. Sensitivity analyses were performed to exclude patients who died within 1, 2, 3, and 7 days of ICU admission. Additionally, a 7-day landmark analysis was conducted to evaluate the effect of SFI treatment on 28-day mortality in patients who survived at least 7 days.
resultsFollowing adjustment for confounding variables via a propensity score model, 154 paired patients were derived from patients who received SFI and those who did not. The infusion of SFI were associated with a lower rate of 28-day mortality rate (9.74% [15/154] vs. 22.73% [35/154]; P = 0.002), prolonged vasopressor-free days (19.35 ± 6.86 vs. 16.64 ± 8.91; P = 0.030) and significantly lower D-dimer levels (3.13 ± 4.25 vs. 4.19 ± 5.11; P = 0.050). No significant difference was found in procalcitonin clearance rate (P = 0.316) or the lactate clearance rate at 72 h.
conclusionAmong critically ill patients with sepsis, adjuvant SFI infusion was associated with improvements in 28-day mortality and organ function recovery. The results need to be verified in further randomized controlled trials to validate these findings and address potential biases, such as immortal time bias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.